364 related articles for article (PubMed ID: 14579518)
21. Hurdles with using in vitro models to predict human blood-brain barrier drug permeability: a special focus on transporters and metabolizing enzymes.
Shawahna R; Decleves X; Scherrmann JM
Curr Drug Metab; 2013 Jan; 14(1):120-36. PubMed ID: 23215812
[TBL] [Abstract][Full Text] [Related]
22. Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs.
Cucullo L; Hossain M; Rapp E; Manders T; Marchi N; Janigro D
Epilepsia; 2007 Mar; 48(3):505-16. PubMed ID: 17326793
[TBL] [Abstract][Full Text] [Related]
23. Delivery of peptides to the brain: emphasis on therapeutic development.
Banks WA
Biopolymers; 2008; 90(5):589-94. PubMed ID: 18335425
[TBL] [Abstract][Full Text] [Related]
24. Methods to assess drug permeability across the blood-brain barrier.
Nicolazzo JA; Charman SA; Charman WN
J Pharm Pharmacol; 2006 Mar; 58(3):281-93. PubMed ID: 16536894
[TBL] [Abstract][Full Text] [Related]
25. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses.
Pardridge WM
Bioconjug Chem; 2008 Jul; 19(7):1327-38. PubMed ID: 18547095
[TBL] [Abstract][Full Text] [Related]
26. A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes.
Nakagawa S; Deli MA; Kawaguchi H; Shimizudani T; Shimono T; Kittel A; Tanaka K; Niwa M
Neurochem Int; 2009; 54(3-4):253-63. PubMed ID: 19111869
[TBL] [Abstract][Full Text] [Related]
27. Predicting penetration across the blood-brain barrier from simple descriptors and fragmentation schemes.
Zhao YH; Abraham MH; Ibrahim A; Fish PV; Cole S; Lewis ML; de Groot MJ; Reynolds DP
J Chem Inf Model; 2007; 47(1):170-5. PubMed ID: 17238262
[TBL] [Abstract][Full Text] [Related]
28. Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position.
Kalvass JC; Polli JW; Bourdet DL; Feng B; Huang SM; Liu X; Smith QR; Zhang LK; Zamek-Gliszczynski MJ;
Clin Pharmacol Ther; 2013 Jul; 94(1):80-94. PubMed ID: 23588303
[TBL] [Abstract][Full Text] [Related]
29. Quantitation of blood-brain barrier ultrastructure.
Stewart PA; Hayakawa K; Farrell CL
Microsc Res Tech; 1994 Apr; 27(6):516-27. PubMed ID: 8012054
[TBL] [Abstract][Full Text] [Related]
30. Molecular Trojan horses for blood-brain barrier drug delivery.
Pardridge WM
Curr Opin Pharmacol; 2006 Oct; 6(5):494-500. PubMed ID: 16839816
[TBL] [Abstract][Full Text] [Related]
31. Current in vitro and in silico models of blood-brain barrier penetration: a practical view.
Vastag M; Keseru GM
Curr Opin Drug Discov Devel; 2009 Jan; 12(1):115-24. PubMed ID: 19152220
[TBL] [Abstract][Full Text] [Related]
32. Retinal selectivity of gene expression in rat retinal versus brain capillary endothelial cell lines by differential display analysis.
Tomi M; Abukawa H; Nagai Y; Hata T; Takanaga H; Ohtsuki S; Terasaki T; Hosoya K
Mol Vis; 2004 Aug; 10():537-43. PubMed ID: 15316464
[TBL] [Abstract][Full Text] [Related]
33. Targeting the brain--surmounting or bypassing the blood-brain barrier.
Potschka H
Handb Exp Pharmacol; 2010; (197):411-31. PubMed ID: 20217538
[TBL] [Abstract][Full Text] [Related]
34. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?
Juillerat-Jeanneret L
Drug Discov Today; 2008 Dec; 13(23-24):1099-106. PubMed ID: 18848640
[TBL] [Abstract][Full Text] [Related]
35. Blood-brain barrier transport of pramipexole, a dopamine D2 agonist.
Okura T; Ito R; Ishiguro N; Tamai I; Deguchi Y
Life Sci; 2007 Apr; 80(17):1564-71. PubMed ID: 17307202
[TBL] [Abstract][Full Text] [Related]
36. Strategy for effective brain drug delivery.
Alam MI; Beg S; Samad A; Baboota S; Kohli K; Ali J; Ahuja A; Akbar M
Eur J Pharm Sci; 2010 Aug; 40(5):385-403. PubMed ID: 20497904
[TBL] [Abstract][Full Text] [Related]
37. Modelling blood-brain barrier partitioning using Bayesian neural nets.
Winkler DA; Burden FR
J Mol Graph Model; 2004 Jul; 22(6):499-505. PubMed ID: 15182809
[TBL] [Abstract][Full Text] [Related]
38. Diketopiperazines as a tool for the study of transport across the blood-brain barrier (BBB) and their potential use as BBB-shuttles.
Teixidó M; Zurita E; Malakoutikhah M; Tarragó T; Giralt E
J Am Chem Soc; 2007 Sep; 129(38):11802-13. PubMed ID: 17764181
[TBL] [Abstract][Full Text] [Related]
39. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals.
Du J; Lu WL; Ying X; Liu Y; Du P; Tian W; Men Y; Guo J; Zhang Y; Li RJ; Zhou J; Lou JN; Wang JC; Zhang X; Zhang Q
Mol Pharm; 2009; 6(3):905-17. PubMed ID: 19344115
[TBL] [Abstract][Full Text] [Related]
40. Exogenous expression of claudin-5 induces barrier properties in cultured rat brain capillary endothelial cells.
Ohtsuki S; Sato S; Yamaguchi H; Kamoi M; Asashima T; Terasaki T
J Cell Physiol; 2007 Jan; 210(1):81-6. PubMed ID: 16998798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
